Biological

T-cell Receptor-engineered T-cells clinical trials

studies test it: 10
open now: 6
in phase 3: 0
first study started: 2018

Keep track of what changes. Save the T-cell Receptor-engineered T-cells studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

TCR-T cells: 6
TCR T Cells: 3
T-cell Receptor-engineered T-cells: 2
T-cell Receptor-engineered T Cells: 2
T-cell Receptor-engineered T-lymphocytes: 2

Development codes

AFNT-111: 1
FIT-001: 1

Studies by the year they started

10 studies that test it; most in 2018 (2)

Studies that test T-cell Receptor-engineered T-cells, by start year
Year	Studies
2018	2
2019	2
2022	2
2023	1
2025	1
2026	2

By phase

A phase 1/2 study counts in both.

Early Phase 1: 3
Phase 1: 7
Phase 2: 1

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms: 2
Carcinoma, Non-Small-Cell Lung: 2
Leukemia, Myeloid, Acute: 1
Colorectal Neoplasms: 1
Carcinoma, Hepatocellular: 1
Carcinoma, Neuroendocrine: 1

Who runs them

Industry 2 · Other 8

Fred Hutchinson Cancer Center (2) · Shenzhen University General Hospital (1) · Beijing DCTY Biotech Co.,Ltd. (1) · Sun Yat-sen University (1) · Fujian Cancer Hospital (1) · Guangzhou FineImmune Biotechnology Co., LTD. (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · TCRCure Biopharma Ltd. (1)

Often tested with

Tested in the same studies.

Fludarabine (4) · Cyclophosphamide (4) · Interleukin-2 (2) · Bendamustine (2) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1)

Studies

Open first, then newest update. How each study uses T-cell Receptor-engineered T-cells is read from its arms, and is right about nine times in ten.